赫赛汀-话题@MedSci

#赫赛汀#

18篇内容 | 1445人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2116409, encodeId=992f2116409c5, content=<a href='/topic/show?id=1fef10530e53' target=_blank style='color:#2F92EE;'>#优赫得#</a>，这个名字厉害，优于<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>的意思, objectTitle=新一代ADC药物优赫得在华获批，晚期乳腺癌迎来治疗新希望！, objectType=article, longId=760765, objectId=24a3e60765ab, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230225/1677298970724_92910.png, objectUrl=/article/show_article.do?id=24a3e60765ab, replyNumber=0, likeNumber=104, createdTime=2023-02-25, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=24a3e60765ab, moduleTitle=新一代ADC药物优赫得在华获批，晚期乳腺癌迎来治疗新希望！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24a3e60765ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410640, encodeId=598414106406a, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=Nat Commun：FOXO3a-miRNA负反馈抑制作用影响HER2阳性乳腺癌的赫赛汀耐药性, objectType=article, longId=212437, objectId=bdbb21243e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdbb21243e30, replyNumber=0, likeNumber=73, createdTime=2021-06-09, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdbb21243e30, moduleTitle=Nat Commun：FOXO3a-miRNA负反馈抑制作用影响HER2阳性乳腺癌的赫赛汀耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdbb21243e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410639, encodeId=26c81410639bf, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=赫赛汀再迎来一对手, objectType=article, longId=184118, objectId=6bd6184118d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd6184118d5, replyNumber=0, likeNumber=76, createdTime=2019-12-05, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd6184118d5, moduleTitle=赫赛汀再迎来一对手, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd6184118d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410638, encodeId=51a4141063883, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=诺奖风向标拉斯克奖花落免疫细胞、赫赛汀发现者和疫苗联盟, objectType=article, longId=179276, objectId=648b1e9276fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=648b1e9276fb, replyNumber=0, likeNumber=87, createdTime=2019-09-12, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=648b1e9276fb, moduleTitle=诺奖风向标拉斯克奖花落免疫细胞、赫赛汀发现者和疫苗联盟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=648b1e9276fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410637, encodeId=c343141063eb3, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=拉斯克奖背后的故事：T细胞B细胞发现与抗癌药赫赛汀的诞生, objectType=article, longId=179274, objectId=b8971e9274f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8971e9274f1, replyNumber=0, likeNumber=91, createdTime=2019-09-12, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8971e9274f1, moduleTitle=拉斯克奖背后的故事：T细胞B细胞发现与抗癌药赫赛汀的诞生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8971e9274f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410636, encodeId=04b214106369e, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=乳腺癌药物赫赛汀纳入医保后需求激增，全国缺货将提高产能, objectType=article, longId=139699, objectId=cbd8139699ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbd8139699ac, replyNumber=0, likeNumber=63, createdTime=2018-06-03, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbd8139699ac, moduleTitle=乳腺癌药物赫赛汀纳入医保后需求激增，全国缺货将提高产能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbd8139699ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410635, encodeId=1934141063586, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药, objectType=article, longId=128870, objectId=4e4b1288e05f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e4b1288e05f, replyNumber=0, likeNumber=0, createdTime=2018-02-06, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e4b1288e05f, moduleTitle=JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e4b1288e05f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410634, encodeId=451914106342b, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=生物类似药领域的里程碑：罗氏赫赛汀安维汀生物类似药获批, objectType=article, longId=105512, objectId=db2e10551207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db2e10551207, replyNumber=0, likeNumber=73, createdTime=2017-07-16, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db2e10551207, moduleTitle=生物类似药领域的里程碑：罗氏赫赛汀安维汀生物类似药获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db2e10551207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410633, encodeId=b7db1410633db, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=98, createdTime=2016-12-28, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410632, encodeId=cc851410632ec, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, objectType=article, longId=73839, objectId=0b9ee38391d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9ee38391d, replyNumber=0, likeNumber=70, createdTime=2016-07-28, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9ee38391d, moduleTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9ee38391d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410631, encodeId=3d3f1410631a8, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者, objectType=article, longId=70016, objectId=04a8e0016c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8e0016c5, replyNumber=0, likeNumber=71, createdTime=2016-06-07, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8e0016c5, moduleTitle=ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8e0016c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410630, encodeId=22e114106302e, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=美国九家癌症中心起诉基因泰克违约偷减抗癌药赫赛汀剂量, objectType=article, longId=64036, objectId=3f9f64036a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f9f64036a0, replyNumber=0, likeNumber=104, createdTime=2016-03-04, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f9f64036a0, moduleTitle=美国九家癌症中心起诉基因泰克违约偷减抗癌药赫赛汀剂量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f9f64036a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410629, encodeId=0eae1410629f2, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=JCO：拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌, objectType=article, longId=46602, objectId=d54d466020a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d54d466020a, replyNumber=0, likeNumber=66, createdTime=2015-02-05, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d54d466020a, moduleTitle=JCO：拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d54d466020a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410628, encodeId=fb05141062809, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=罗氏遭遇巨大挫折，乳腺癌新药Kadcyla和Perjeta效果不如赫赛汀？, objectType=article, longId=44499, objectId=fea6444992b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fea6444992b, replyNumber=0, likeNumber=116, createdTime=2014-12-25, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fea6444992b, moduleTitle=罗氏遭遇巨大挫折，乳腺癌新药Kadcyla和Perjeta效果不如赫赛汀？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fea6444992b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410627, encodeId=5c88141062ed6, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=JCO：赫赛汀+辅助化疗提高乳腺癌生存率, objectType=article, longId=41682, objectId=8f3f41682e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f3f41682e3, replyNumber=0, likeNumber=109, createdTime=2014-10-26, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f3f41682e3, moduleTitle=JCO：赫赛汀+辅助化疗提高乳腺癌生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f3f41682e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410626, encodeId=8d26141062658, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀, objectType=article, longId=33006, objectId=1aa333006b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1aa333006b4, replyNumber=0, likeNumber=79, createdTime=2014-04-10, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1aa333006b4, moduleTitle=Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1aa333006b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410625, encodeId=d0c11410625cb, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=罗氏禁止仿制药对手使用赫赛汀进行对照, objectType=article, longId=30538, objectId=e5d6305381e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5d6305381e, replyNumber=0, likeNumber=99, createdTime=2014-02-14, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5d6305381e, moduleTitle=罗氏禁止仿制药对手使用赫赛汀进行对照, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5d6305381e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410624, encodeId=8e1914106247c, content=<a href='/topic/show?id=08ad9264106' target=_blank style='color:#2F92EE;'>#赫赛汀#</a>, objectTitle=Mol Cell：癌症细胞对赫赛汀产生耐药的原因, objectType=article, longId=8127, objectId=4d72812e85, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d72812e85, replyNumber=0, likeNumber=82, createdTime=2012-07-25, rootId=0, userName=wrj0122, userId=05462758965, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d72812e85, moduleTitle=Mol Cell：癌症细胞对赫赛汀产生耐药的原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d72812e85)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

赫赛汀

2020-05-29

showtest (审核中...)

前往app查看评论内容

#优赫得#，这个名字厉害，优于#赫赛汀#的意思

新一代ADC药物优赫得在华获批，晚期乳腺癌迎来治疗新希望！

2023-02-25发表于上海

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

Nat Commun：FOXO3a-miRNA负反馈抑制作用影响HER2阳性乳腺癌的赫赛汀耐药性

2021-06-09

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

赫赛汀再迎来一对手

2019-12-05

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

诺奖风向标拉斯克奖花落免疫细胞、赫赛汀发现者和疫苗联盟

2019-09-12

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

拉斯克奖背后的故事：T细胞B细胞发现与抗癌药赫赛汀的诞生

2019-09-12

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

乳腺癌药物赫赛汀纳入医保后需求激增，全国缺货将提高产能

2018-06-03

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药

2018-02-06

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

生物类似药领域的里程碑：罗氏赫赛汀安维汀生物类似药获批

2017-07-16

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2016-12-28

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据

2016-07-28

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

ASCO 2016：赫赛汀生物仿制药或可有效治疗HER2阳性的乳腺癌患者

2016-06-07

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

美国九家癌症中心起诉基因泰克违约偷减抗癌药赫赛汀剂量

2016-03-04

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

JCO：拉帕替尼+希罗达VS赫赛汀+希罗达用于Her-2阳性转移性乳腺癌

2015-02-05

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

罗氏遭遇巨大挫折，乳腺癌新药Kadcyla和Perjeta效果不如赫赛汀？

2014-12-25

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

JCO：赫赛汀+辅助化疗提高乳腺癌生存率

2014-10-26

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀

2014-04-10

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

罗氏禁止仿制药对手使用赫赛汀进行对照

2014-02-14

wrj0122 (审核中...)

前往app查看评论内容

#赫赛汀#

Mol Cell：癌症细胞对赫赛汀产生耐药的原因

2012-07-25

科室
- - 订阅+
  - 更多科室
工具
服务